These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 32379831)

  • 1. Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant.
    Tsuruda M; Yoshino H; Okamura S; Kuroshima K; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    PLoS One; 2020; 15(5):e0232545. PubMed ID: 32379831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma.
    Greenberg JW; Kim H; Moustafa AA; Datta A; Barata PC; Boulares AH; Abdel-Mageed AB; Krane LS
    Sci Rep; 2021 May; 11(1):10200. PubMed ID: 33986386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
    J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
    Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.
    Adelaiye-Ogala R; Damayanti NP; Orillion AR; Arisa S; Chintala S; Titus MA; Kao C; Pili R
    Cancer Res; 2018 Jun; 78(11):2886-2896. PubMed ID: 29572225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
    Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
    EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
    Sakai I; Miyake H; Fujisawa M
    BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
    Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
    Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splice variants of lysosome‑associated membrane proteins 2A and 2B are involved in sunitinib resistance in human renal cell carcinoma cells.
    Nishikawa R; Osaki M; Sasaki R; Ishikawa M; Yumioka T; Yamaguchi N; Iwamoto H; Honda M; Kabuta T; Takenaka A; Okada F
    Oncol Rep; 2020 Nov; 44(5):1810-1820. PubMed ID: 32901843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nesprin1 Deficiency Is Associated with Poor Prognosis of Renal Cell Carcinoma and Resistance to Sunitinib Treatment.
    Fukushima T; Kobatake K; Miura K; Takemoto K; Yamanaka R; Tasaka R; Kohada Y; Miyamoto S; Sekino Y; Kitano H; Goto K; Ikeda K; Goriki A; Hieda K; Kaminuma O; Hinata N
    Oncology; 2024; 102(10):868-879. PubMed ID: 38442705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis.
    Wu Z; Peng Y; Xiong L; Wang J; Li Z; Ning K; Deng M; Wang N; Wei W; Li Z; Dong P; Yu C; Zhou F; Zhang Z
    Cancer Med; 2022 Oct; 11(19):3674-3686. PubMed ID: 35476809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma.
    Zhang C; Lu X; Huang J; He H; Chen L; Liu Y; Wang H; Xu Y; Xing S; Ruan X; Yang X; Chen L; Xu D
    Clin Transl Med; 2021 Feb; 11(2):e328. PubMed ID: 33634984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA.
    Qu L; Ding J; Chen C; Wu ZJ; Liu B; Gao Y; Chen W; Liu F; Sun W; Li XF; Wang X; Wang Y; Xu ZY; Gao L; Yang Q; Xu B; Li YM; Fang ZY; Xu ZP; Bao Y; Wu DS; Miao X; Sun HY; Sun YH; Wang HY; Wang LH
    Cancer Cell; 2016 May; 29(5):653-668. PubMed ID: 27117758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lefty A is involved in sunitinib resistance of renal cell carcinoma cells via regulation of IL-8.
    Cui N; Han Q; Cao Q; Wang K; Zhou X; Hou P; Liu C; Chen L; Xu L
    Biol Chem; 2021 Sep; 402(10):1247-1256. PubMed ID: 34363384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via TFE3 signaling pathway.
    Li L; Zhao S; Liu Z; Zhang N; Pang S; Liu J; Liu C; Fan Y
    Cell Death Dis; 2021 Feb; 12(2):220. PubMed ID: 33637706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
    Liu W; Ren D; Xiong W; Jin X; Zhu L
    J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis.
    Huang KB; Pan YH; Shu GN; Yao HH; Liu X; Zhou M; Wei JH; Chen ZH; Lu J; Feng ZH; Chen W; Han H; Zheng ZS; Luo JH; Zhang JX
    Cancer Lett; 2021 Dec; 523():121-134. PubMed ID: 34626691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.